In the Western world, LinkedIn is a staple for many recruitment professionals. It has proven to be a powerful tool for networking, talent sourcing and job postings. But in Japan, people don’t use LinkedIn very much.Here’s why LinkedIn isn’t popular…
HOME > BUSINESS
BUSINESS
- Daiichi Sankyo Initiates Multinational ENSURE-AF Study of Edoxaban in the US, Europe
April 4, 2014
- Sawai Stands Out with Operating Profit Rate of 25% in 3rd Quarter, Moving into Top Level of the Industry
April 4, 2014
- Sales Rep Wrote Out Side Effect Grades for Doctors in SIGN Trial: Panel
April 3, 2014
- Independent Panel Finds Transgression of Fair Competition Code, Cover-Up over SIGN Trial
April 3, 2014
- COO Weber Wants Takeda to Be Global Leader
April 3, 2014
- Mochida Aims for Sales of 110 Billion Yen with Generic Sales of Over 10 Billion Yen in FY2016
April 3, 2014
- Astellas Establishes “Regenerative Medicine Unit”; Aims to Establish Basic Technologies within 1 to 2 Years
April 3, 2014
- 2014 Japan Debut of Prostate Cancer Drugs to End Dearth of CRPC Treatments
April 2, 2014
- Latuda Granted European Regulatory Approval: DSP, Takeda
April 2, 2014
- Abbott Japan Takes Over Marketing Approval for Duphaston from Daiichi Sankyo
April 2, 2014
- Kyowa Kirin Files Nesp in Japan for Anemia in Myelodysplastic Syndrome
April 2, 2014
- Japan Vaccine Files NDA for Pneumococcal Conjugate Vaccine in Japan
April 2, 2014
- US Biotech NPS Takes Aim at Japan Debut around 2017
April 1, 2014
- Torii Puts Off Launch of Sublingual Hay Fever Drug
April 1, 2014
- Otsuka Acquires Rights for Dacogen from Eisai US Subsidiary
April 1, 2014
- Shionogi Predicts Milder Patent Cliff for Crestor after AZ Deal: Pres.
March 31, 2014
- AnGes MG to Procure 500 Million Yen through Allocation of New Shares to Third Party, to Invest in Orphan Drug Licensing
March 31, 2014
- Suglat Tops February “Mind Share” Ranking in GP Market
March 31, 2014
- Uniform Pricing of Generics into 3 Price Brackets Will Make It More Difficult to Set Invoice Prices: Pres. Yoshiwaka of Daiichi Sankyo Espha
March 28, 2014
- Takeda, Otsuka to Copromote Takeda’s Novel Acid-Related Disease Treatment Vonoprazan
March 28, 2014
ページ
An increasing number of companies in Japan are showing an eagerness to snatch up “drug loss” assets. As of this…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…